Although evidence of the effectiveness of Cmab monotherapy remains limited, the INTERLINK-1 study,31 which was a randomized controlled trial comparing the efficacy of monalizumab + Cmab versus Cmab monotherapy in patients with RM-HNSCC previously treated with platinum and an anti-PD-1 antibody, reported an ORR of 23.9%, median PFS of 3.8 months, and median OS of 8.6 months in patients on Cmab monotherapy. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.